Last reviewed · How we verify
NCT05615233: TACAD
TACAD Program for Asian American Family Caregivers of Persons Living With Alzheimer's Disease
NA trial testing TACAD in Alzheimer Disease in 54 participants. Completed in 31 August 2025.
31 May 2025
Quick facts
| Lead sponsor | University of Texas at Austin |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 54 |
| Start date | 5 April 2024 |
| Primary completion | 31 May 2025 |
| Estimated completion | 31 August 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- TACAD
- Alzheimer's Association website
Conditions studied
- Alzheimer Disease — all drugs for Alzheimer Disease →
Sponsor
University of Texas at Austin
Who can join
Adults 40 to 65, female only, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the proposed study is to preliminarily evaluate Technology-based information and coaching/support program that is tailored for Asian American midlife women who are family caregivers of patients living with Alzheimer's disease (TACAD) in improving health outcomes of Asian American midlife women who are family caregivers of persons living with Alzheimer's disease (AACA) and their care recipients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05615233
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alzheimer Disease
Currently open trials in the same condition.
- NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
- NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
- NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
- NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
- NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting
Other University of Texas at Austin trials
Trials by the same sponsor.
- NCT07319234 — Development of MENU Protocol · NA · not yet recruiting
- NCT07480109 — Increased Dietary Protein Intake During GLP-1 Medication Use (in Middle-aged Women With Overweight/Obesity) · NA · not yet recruiting
- NCT07069413 — Sibwatch: Optimizing Intervention Options for Infants and Toddler Siblings of Autistic Children · NA · not yet recruiting
- NCT07370311 — A Culturally Adapted Decision Aid Intervention to Support Chinese American Dementia Caregivers in Feeding-Related Decisi · NA · not yet recruiting
- NCT07441122 — Enhancing Attention in Elderly Using a Brain-Computer-Interface · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05615233 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Texas at Austin
- Last refreshed: 24 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05615233.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing